Abstract: Embodiments of the invention provide processes to selectively form a cobalt layer on a copper surface over exposed dielectric surfaces. In one embodiment, a method for capping a copper surface on a substrate is provided which includes positioning a substrate within a processing chamber, wherein the substrate contains a contaminated copper surface and a dielectric surface, exposing the contaminated copper surface to a reducing agent while forming a copper surface during a pre-treatment process, exposing the substrate to a cobalt precursor gas to selectively form a cobalt capping layer over the copper surface while leaving exposed the dielectric surface during a vapor deposition process, and depositing a dielectric barrier layer over the cobalt capping layer and the dielectric surface.

Abstract: Improved artificial intelligence computer systems actively and/or passively provide end-users with information from firm data systems to help the end-user perform the end-user's job functions. In a passive implementation, the system can prioritize emails for a user, craft consistent responses to multiple email inquiries on the same topic, and/or craft responses whose content is drawn from a library of electronic documents. In an active implementation, the system comprises AI agents associated with individual databases of the system, where the AI agents are tuned to retrieve data from their associated database in response to a query from the end-user.

Abstract: Improved artificial intelligence computer systems actively and/or passively provide end-users with information from firm data systems to help the end-user perform the end-user's job functions. In a passive implementation, the system can prioritize emails for a user, craft consistent responses to multiple email inquiries on the same topic, and/or craft responses whose content is drawn from a library of electronic documents. In an active implementation, the system comprises AI agents associated with individual databases of the system, where the AI agents are tuned to retrieve data from their associated database in response to a query from the end-user.

Abstract: A computerized method of identifying accounts stored in a database of an account management system, for review under jurisdictionally relevant CIP/AML/KYC requirements is described, as is a computerized account database access tool having a data extraction module, an inclusion rules module, an exclusion rules module and a merge and aggregate module.

Abstract: Provided herein are methods for identifying individuals diagnosed with a cell proliferative disorder that will benefit from treatment with a telomerase inhibitor compound. Also provided herein are methods for treating these individuals with telomerase inhibitor compounds.

Abstract: Provided herein are methods for identifying individuals diagnosed with a cell proliferative disorder that will benefit from treatment with a telomerase inhibitor compound. Also provided herein are methods for treating these individuals with telomerase inhibitor compounds.

Abstract: A computerized method of identifying accounts stored in a database of an account management system, for review under jurisdictionally relevant CIP/AML/KYC requirements is described, as is a computerized account database access tool having a data extraction module, an inclusion rules module, an exclusion rules module and a merge and aggregate module.

Abstract: Provided herein are methods for identifying individuals diagnosed with a cell proliferative disorder that will benefit from treatment with a telomerase inhibitor compound. Also provided herein are methods for treating these individuals with telomerase inhibitor compounds. The methods comprise identifying individuals who will benefit from said treatment based on the average relative length of telomeres in cancer cells from said individuals.

Abstract: Provided herein are methods for identifying individuals diagnosed with a cell proliferative disorder that will benefit from treatment with a telomerase inhibitor compound. Also provided herein are methods for treating these individuals with telomerase inhibitor compounds.

Abstract: Provided herein are methods for identifying individuals diagnosed with a cell proliferative disorder that will benefit from treatment with a telomerase inhibitor compound. Also provided herein are methods for treating these individuals with telomerase inhibitor compounds.

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-005 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-005 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer com\ pounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-005 expression or activity, comprising: contacting a candidate compound with a TAT-005 and detecting the presence or absence of binding between said compound and said TAT-005, or detecting a change in TAT-005 expression or activity. Methods are also included for the identification of compounds that modulate TAT-005 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-005 expression or activity.

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-001 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-001 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-001 expression or activity, comprising: contacting a candidate compound with a TAT-001 and detecting the presence or absence of binding between said compound and said TAT-001, or detecting a change in TAT-001 expression or activity.

Abstract: Systems, methods, computer programming product, and databases for virtual mass spectrometry (VMS) enable the identification of polypeptides in samples without acquisition of MS/MS fragmentation spectra. Methods according to the invention employ databases containing records corresponding to polypeptides potentially present in samples. In addition to identifying polypeptides, such databases may be used for other purposes, including for example to correct experimental data, e.g., for analytical systemic errors.

Abstract: The present invention features computer methods and systems for comparing biomolecules across biological samples. In these methods, mass spectrometry measurements are obtained on biomolecules in two or more samples. These measurements are then processed and analyzed by the methods described herein to render them more comparable. We refer to this technology as “Constellation Mapping” (CM). The resulting data, constellation maps, can be used to compare the abundance of biomolecules across samples, and, when done in real time, can be used to select differentially abundant biomolecules for subsequent LC/MS-MS.

Abstract: The present invention features computer methods and systems for comparing biomolecules across biological samples. In these methods, mass spectrometry measurements are obtained on biomolecules in two or more samples. These measurements are then processed and analyzed by the methods described herein to render them more comparable. We refer to this technology as “Constellation Mapping” (CM). The resulting data, constellation maps, can be used to compare the abundance of biomolecules across samples, and, when done in real time, can be used to select differentially abundant biomolecules for subsequent LC/MS-MS.

Abstract: The present invention features computer methods and systems for comparing biomolecules across biological samples. In these methods, mass spectrometry measurements are obtained on biomolecules in two or more samples. These measurements are then processed and analyzed by the methods described herein to render them more comparable. We refer to this technology as “Constellation Mapping” (CM). The resulting data, constellation maps, can be used to compare the abundance of biomolecules across samples, and, when done in real time, can be used to select differentially abundant biomolecules for subsequent LC/MS-MS.